Randomized phase II study of gemcitabine administered at a fixed dose rate or in combination with cisplatin, docetaxel, or irinotecan in patients with metastatic pancreatic cancer: CALGB 89904

Matthew H. Kulke, Margaret A. Tempero, Donna Niedzwiecki, Donna R. Hollis, Hedy L. Kindler, Michael Cusnir, Peter C. Enzinger, Stefan M. Gorsch, Richard M. Goldberg, Robert J. Mayer

Research output: Contribution to journalArticle

65 Scopus citations

Abstract

Purpose: The relative value of gemcitabine-based combination chemotherapy therapy and prolonged infusions of gemcitabine in patients with advanced pancreatic cancer remains controversial. We explored the efficacy and toxicity of gemcitabine administered at a fixed dose rate or in combination with cisplatin, docetaxel, or irinotecan in a multi-institutional, randomized, phase II study. Patients and Methods: Patients with metastatic pancreatic cancer were randomly assigned to one of the following four regimens: gemcitabine 1,000 mg/m2 on days 1, 8, and 15 with cisplatin 50 mg/m2 on days 1 and 15 (arm A); gemcitabine 1,500 mg/m2 at a rate of 10 mg/m 2/min on days 1, 8, and 15 (arm B); gemcitabine 1,000 mg/m 2 with docetaxel 40 mg/m2 on days 1 and 8 (arm C); or gemcitabine 1,000 mg/m2 with irinotecan 100 mg/m2 on days 1 and 8 (arm D). Patients were observed for response, toxicity, and survival. Results: Two hundred fifty-nine patients were enrolled onto the study, of whom 245 were eligible and received treatment. Anticipated rates of myelosuppression, fatigue, and expected regimenspecific toxicities were observed. The overall tumor response rates were 12% to 14%, and the median overall survival times were 6.4 to 7.1 months among the four regimens. Conclusion: Gemcitabine/cisplatin, fixed dose rate gemcitabine, gemcitabine/docetaxel, and gemcitabine/irinotecan have similar antitumor activity in metastatic pancreatic cancer. In light of recent negative randomized studies directly comparing several of these regimens with standard gemcitabine, none of these approaches can be recommended for routine use in patients with this disease.

Original languageEnglish (US)
Pages (from-to)5506-5512
Number of pages7
JournalJournal of Clinical Oncology
Volume27
Issue number33
DOIs
StatePublished - Nov 20 2009

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Randomized phase II study of gemcitabine administered at a fixed dose rate or in combination with cisplatin, docetaxel, or irinotecan in patients with metastatic pancreatic cancer: CALGB 89904'. Together they form a unique fingerprint.

  • Cite this

    Kulke, M. H., Tempero, M. A., Niedzwiecki, D., Hollis, D. R., Kindler, H. L., Cusnir, M., Enzinger, P. C., Gorsch, S. M., Goldberg, R. M., & Mayer, R. J. (2009). Randomized phase II study of gemcitabine administered at a fixed dose rate or in combination with cisplatin, docetaxel, or irinotecan in patients with metastatic pancreatic cancer: CALGB 89904. Journal of Clinical Oncology, 27(33), 5506-5512. https://doi.org/10.1200/JCO.2009.22.1309